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AIM: To determine induced sputum cell counts and
interleukin-8 (IL-8), tumor necrosis factor alpha
(TNF-a) and leukotriene B4 (LTB4) levels as markers
of neutrophilic inflammation in moderate persistent
asthma, and to evaluate the response to inhaled
steroid therapy.
Methods: Forty-five moderate asthmatic patients and
10 non-smoker controls were included in this study.
All patients received inhaled corticosteroid (800 mgo f
budesonide) for 12 weeks. Before and after treatment
pulmonary function tests were performed, and symp-
tom scores were determined. Blood was drawn for
analysis of serum inflammatory markers, and sputum
was induced.
Results: Induced sputum cell counts and inflamma-
tory markers were significantly higher in patients
with asthma than in the control group. The induced
sputum eosinophil counts of 12 patients (26%) were
found to be less than 5%, the non-eosinophilic group,
and sputum neutrophil counts, IL-8 and TNF-a levels
were significantly higher than the eosinophilic group
(neutrophil, 509 /14% versus 199 /10%, pB /0.01).
In both groups, there was a significant decrease in
sputum total cell counts and serum and sputum IL-8,
TNF-a and LTB4 levels after the treatment. There was
no change in sputum neutrophil counts. Although
the sputum eosinophil count decreased only in the
eosinophilic subjects, there was no significant differ-
ence in inflammatory markers between the groups.
The symptom scores were significantly improved
after treatment, while the improvement did not reach
statistical significance on pulmonary function test
parameters.
Conclusion: Notably, in chronic asthma there is a
subgroup of patients whose predominant inflamma-
tory cells are not eosinophils. Sputum neutrophil
counts and neutrophilic inflammatory markers are
significantly higher in these patients. In the non-
eosinophilic group, inhaled steroid caused an impor-
tant decrease in inflammatory markers; however,
there was no change in the sputum eosinophil and
neutrophil counts.
Key words: Asthma, Sputum eosinophilia, Neutrophilic
inﬂammation, Interleukin-8, Tumor necrosis factor alpha
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Introduction
Eosinophils, mast cells and T lymphocytes are
involved in the pathogenesis of airway inflammation
in asthma.
1 However, there is an increasing recogni-
tion of non-eosinophilic, especially neutrophilic,
forms of airway inflammation in asthmatic patients.
2,3
Prominent neutrophilic inflammation has been de-
monstrated in severe refractory asthma, fatal asthma,
exacerbation periods, occupational asthma and noc-
turnal asthma.
4 8
Recently, heterogeneity of airway inflammation
was reported in persistent asthmatics.
9 Since corti-
costeroids are the cornerstone in asthma treatment, it
is important to identify whether the presence of
neutrophilic inflammation affects the response to
inhaled steroids in asthmatic patients.
The pathogenetic mechanism of neutrophil recruit-
ment in the airways is not well understood. It has not
been clarified whether neutrophils are the main part
of the inflammatory process, especially in chronic
and severe asthmatics, or whether it is a consequence
of the steroid treatment, since it is known that
steroids inhibit the apoptosis of neutrophils and
increase their survival in the airways.
10
Several inflammatory markers have been investi-
gated and found to be associated with chemotaxis
and accumulation of neutrophils in the airways of
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285patients with asthma and chronic obstructive pul-
monary disease (COPD). The most important and
the most widely investigated markers include inter-
leukin-8 (IL-8), tumor necrosis factor alpha (TNF-a)
and leukotriene B4 (LTB4).
In this study, we speculated that the presence of
non-eosinophilic inflammation in the asthmatic air-
ways might be associated with IL-8, TNF-a, and LTB4
levels, and it might affect the response to inhaled
steroid. We used induced sputum as a novel method
of evaluating airway inflammation and investigated
the effect of inhaled steroid on induced sputum cell
counts and IL-8, TNF-a, and LTB4 in eosinophilic and
non-eosinophilic asthmatics.
Materials and methods
Patients
Asthma was diagnosed by a history of recurrent
wheezing and chest tightness, and was confirmed
by reversible airway obstruction suggested by   /12%
or 200 ml of improvement in FEV1 (forced expiratory
volume in one second) after 200 mg of salbutamol
inhalation.
1 Forty-five patients classified as moderate
persistent asthma according to GINA (Global Initia-
tive for Asthma) guidelines volunteered to participate
in the study. Ten age-matched non-smokers were
used as the control group. The inclusion criteria for
the study group were; FEV1 or PEF (peak expiratory
flow)   /60% but B /80% predicted, presence of daily
asthma symptoms, non-smoker or ex-smoker for
more than 5 years, no exacerbations in the past 3
months and no history of cardiopulmonary disease
other than asthma. Patients were excluded from the
study if they failed to meet the inclusion criteria, had
inadequate sputum despite three induction proce-
dures on separate days, had received systemic
corticosteroids during the previous 6 weeks or had
clinical evidence of a respiratory tract infection. The
study was approved by the medical ethics committee
of Kocaeli University School of Medicine and written
informed consent was obtained from all participants.
Study design
All selected patients ceased using their current
medications but was allowed to use an inhaled
short-acting beta-2 agonist as needed during a 15-
day run-in period. All patients received 800 mg/day of
inhaled budesonide (Pulmicort turbuhaler 2  /400 mg;
AstraZeneca, Lund, Sweden) for 12 weeks. Symptom
scores were recorded, spirometry was performed,
blood was drawn for measurement of serum inflam-
matory markers and sputum was induced by inhala-
tion of hypertonic saline solution before and after the
treatment period. Patients were classified into two
groups as eosinophilic (E) and non-eosinophilic (NE)
according to their baseline sputum eosinophil counts.
The effects of corticosteroid on the outcome measure-
ments were compared between the groups. The study
design is shown in Fig. 1.
Sputum induction
The sputum was induced as described by Pin et al.
11
All subjects were pretreated with 200 mg of salbuta-
mol administered by metered dose inhaler (Volu-
matic). For the induction process, a Pulmo-Aide
(Brooklyn, NY, USA) ultrasonic nebulizer with an
output of 0.35 ml/min and a particle size of 5 mm was
used and 3% hypertonic saline was nebulized. The
nebulization time consisted of 5-min intervals until a
maximum nebulization time of 30 min. PEF was
measured after each period of inhalation. Subjects
were asked to rinse their mouth and swallow the
water and blow the nose to minimize contamination
with saliva and postnasal drip. They were then
encouraged to cough sputum into a sterile container.
The procedure was continued until either a sufficient
amount of sputum was obtained or the maximum
nebulization time of 30 min was reached.
12
Sputum processing
The sputum samples were processed within 2 h
according to the validated protocol by Popov et al.
with modifications.
13 The volume of induced sput-
um was determined and mixed with an equal
volume of 1% sputalysin (dithiothreitol; Sigma, Milan,
Italy) freshly diluted to 0.1% by the addition of
distilled water. The mixture was incubated at room
45 patients with moderate
persistent asthma
15 day        run-in
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FIG. 1. Study design. PFT, pulmonary function test; ISEC,
induced sputum eosinophil count.
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every 5 min to ensure homogenization and maximize
cell dispersion. To stop the effect of dithiothreitol on
the cell suspension, an equal volume of phosphate-
buffered saline was added. The mixture was then
centrifuged at 1500 rpm for 10 min. Supernatants
were aspirated and stored at   /708C for later analysis
of inflammatory markers. The cell pellets were
resuspended with phosphate-buffered saline to ob-
tain a final volume of 2 /5 ml, then filtered thorough a
gauze (pore size approximately 1 mm) to remove
mucus and cell debris.
The total cell counts were performed in a hemo-
cytometer (Thoma, Marienfeld GmbH, Baden-Wu ¨rt-
tenberg, Germany). The cell suspension was adjusted
to 1  /10
6 cells/ml and cytospin slides were prepared
by using 50 ml of the cell suspension (Model 3
cytospin; Shandon Scientific, Sewickley, PA, USA).
Slides were air-dried and stained by May /
Gru ¨nwald /Giemsa; 200 /400 non-squamous cells
were counted by the blinded investigator (cyto-
pathologist). If   /80% of the cells consisted of
squamous cells, the quality of the sputum sample
was judged to be unsatisfactory and excluded from
the analysis.
Fluid phase measurements
The IL-8 and TNF-a levels in the supernatant
of induced sputum were assessed by enzyme-
linked immunosorbent assay (CytELISA; Cytimmune
Sciences Inc., Rockville, MD, USA). The results were
expressed as picograms per liter and adjusted for the
dilution factor. For IL-8 the sensitivity was 25 pg/ml,
the intra-assay precision was 0.6 /2% and the inter-
assay precision was 1.96 /6.13%. For TNF-a the
sensitivity was 4.8 pg/ml, the range of detection
was 15.6 /1000 pg/ml, the intra-assay variation was
9 /8.3% and the inter-assay variation was 9 /10.8%.
LTB4 levels were also measured by enzyme immu-
noassay (DRG International Inc., Mountainside, NJ,
USA) after prior purification of C18 columns (Altech,
Los Altos, CA, USA). The sensitivity was 19.4 pg/ml,
the intra-assay precision was 5.9 /6.8% and the inter-
assay precision was 5 /16.5%.
Blood was collected in tubes (Becton Dickinson,
Franklin Lakes, NJ, USA, Vacutainer SST) for mea-
surement of serum inflammatory markers and incu-
bated at room temperature for 60 /120 min. They
were then centrifuged at 1300  /g for 10 min. The
serum was aspirated and stored at   /208C for later
analysis of serum IL-8, TNF-a and LTB4 levels.
Pulmonary function tests
Spirometry was performed using a Sensormedics
(Yorba Linda, CA, USA) Vmax 20C. FEV1, FVC,
FEV1/FVC (forced vital capacity) and VC (vital
capacity) were measured. PEF was recorded using a
peak flow meter before each sputum induction
procedures.
Symptom score
The total symptom scores were recorded by using a
questionnaire including day /night asthma symp-
toms, daily beta-2 agonist use and cough frequency.
14
Statistical analysis
All statistical analysis was performed using the SPSS
program. Data were expressed as means9 /standard
deviation. Between-group-change outcome variables
were determined by non-parametric Mann /Whitney
U-test. Within-group-change outcome variables were
compared with the Wilcoxon paired test. Symptom
scores were determined by chi-squared analysis.
PB /0.05 was considered significant.
Results
In total, 45 patients met the inclusion criteria and
were enrolled. Three of them were excluded because
of an exacerbation during the run-in period. The
clinical characteristics of the study population are
presented in Table 1.
Table 1. The clinical characteristics of the study population
Eosinophilic Non-eosinophilic Control
n 33 12 10
Sex (male/female) 4/29 2/10 3/7
Age (years) 56.39 /15 549 /11.5 459 /7
$
Disease duration (years) 10.39 /61 9 9 /10.4*  /
Atopy 14 (42%) 4 (33%)* 0
$
FEV1 (% predicted) 75.39 /22.4 73.49 /16.4 959 /12
$
FVC (% predicted) 849 /18.4 849 /11 969 /15
$
FEV1/FVC (%) 67.39 /11 649 /88 7 9 /9
$
Ex-smokers (smoking pack-years) 5 (149 /7.5) 4 (189 /9) 0
*pB /0.05 eosinophilic versus non-eosinophilic subjects.
$pB /0.05 control versus asthmatic subjects.
Effectiveness of inhaled steroids in asthmatics
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jects with baseline sputum eosinophil counts less
than 5%. Both clinical and functional features of E
and NE patients were compared. Age, sex and
pulmonary function tests were similar between the
groups. Duration of the disease was found to be
longer in the NE group than in the E group (pB /0.05)
and NE patients were likely to be non-atopic. There
were no current smokers in the study population and
the prevalence of ex-smokers was similar between
the groups (Table 1).
Sputum cell counts
When compared with normal subjects, there was an
increase in baseline sputum total cell, eosinophil and
neutrophil counts in asthmatic patients. Among
asthmatic patients, sputum total cell counts and
neutrophil counts were found to be higher in the
NE subjects than in the E subjects (Table 2). Other cell
types were similar between the groups.
After the treatment period the E subjects had a
significant decrease in sputum eosinophil counts
while there was no change in the NE subjects (Table
3 and Fig. 2). Also, no decrease was found with
inhaled corticosteroid treatment on sputum neutro-
phil counts of either NE or E groups (Table 3, Fig. 2).
The intensity of the sputum cellularity, as reflected
by the total cell counts were significantly decreased
in both groups (Table 3).
Sputum and serum inflammatory markers
Both sputum and serum inflammatory markers were
significantly higher in the subjects with asthma
compared with the normal subjects (Table 2). Sub-
jects with NE asthma had higher sputum and serum
IL-8, TNF-a levels and higher sputum LTB4 levels
than those with E asthma.
Although inhaled corticosteroid caused a signifi-
cant reduction in these inflammatory markers, this
decrease did not reach statistical significance be-
tween the groups (Table 3).
Clinical and functional measurements
Baseline symptom scores and pulmonary functions
were similar between the groups. After the treatment
period, all patients experienced significant improve-
ments in symptom scores. FEV1 levels increased with
treatment, although the increase was not statistically
significant either in NE or in E asthma.
Tolerability
Sputum induction was well tolerated. Four patients
required more than one induction procedure to
obtain sufficient amount of sputum. None of the
patients quit the treatment. Three patients were
excluded from the study during the run-in period
because of an exacerbation.
Discussion
In this study we have demonstrated that the non-
eosinophilic form of a moderate persistent asthma is
associated with neutrophilic inflammation and in-
crease in IL-8, TNF-a and LTB4 levels.
The non-eosinophilic form has been identified
even in stable asthmatic patients. It is now accepted
that there is at least two distinct patterns of airway
inflammation in asthma. Jatakanon et al. have
demonstrated increased neutrophil numbers and IL-
8 levels in severe persistent asthmatics.
4 Besides
disease severity, Pavord et al. have found that non-
eosinophilic inflammation was associated with smok-
ing and atopy, since the NE patients in their study
group were more likely to be non-atopic and current
smokers.
15 NE asthma was also shown to be asso-
ciated with age and disease duration.
9 In our
study, we found that neutrophilic inflammation is
related with disease duration and atopy. Together
these data suggest that older, non-atopic patients
with a more severe airway obstruction and longer
disease duration tend to have non-eosinophilic
airway inflammation.
Besides these clinical parameters several inflam-
matory markers have been thought to be associated
with non-eosinophilic inflammation in asthma.
Table 2. Comparison of baseline induced sputum cell counts and inﬂammatory markers in asthmatics and controls
Eosinophilic Non-eosinophilic Control
Total cell count (  /10
6/g) 1.129 /0.5* 1.759 /0.7 0.39 /0.2
$
Eosinophil (%) 27.59 /14* 49 /2.3 1.49 /1.3
$
Neutrophil (%) 209 /10.3* 509 /15 279 /14
Lymphocyte (%) 239 /18 189 /10.4 229 /13.3
Macrophage (%) 309 /17.2 289 /13.4 499 /17.4
$
IL-8 (pg/ml) 5739 /173* 8629 /289 2279 /12
$
TNF-a (pg/ml) 4409 /120* 6249 /128 2199 /49
$
LTB4 (pg/ml) 139 /9* 189 /9 0.849 /0.4
$
*pB /0.05 eosinophilic versus non-eosinophilic subjects.
$pB /0.05 control versus asthmatic subjects.
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IL-8, which is a potent neutrophil chemoattractant
and activator.
16 It is likely to be involved in the
recruitment of neutrophils in the airways of patients
with COPD.
17,18 It is also shown to correlate with the
sputum neutrophil counts in patients with asthma.
9
Chalmers et al. have demonstrated high sputum IL-8
levels in asthmatic smokers and suggested that
neutrophilic inflammation in asthma is associated
with smoking.
19 However, no current smokers were
included and the prevalence of ex-smokers was
similar between the groups in our study. This finding
suggests that only smoking history is not enough to
explain the high levels of sputum IL-8 levels in some
asthmatic patients.
TNF-a has been demonstrated both in COPD and
asthma.
18 It is derived from macrophages, mast cells
or other inflammatory cells.
20 In asthma, TNF-a is
known to upregulate the expression of cell adhesion
molecules. We found that an increased level of TNF-a
is associated with neutrophil counts. Similarly pre-
vious studies have demonstrated the correlation
between neutrophil counts and TNF-a levels, so it
is possible to suggest that TNF-a is one of the
important inflammatory markers, which are respon-
sible for neutrophil recruitment in the airways.
LTB4 is a lipid mediator that is thought to play an
important role in the pathogenesis of COPD. Cystei-
nyl leukotrienes are found to increase in induced
sputum samples of asthmatic patients.
21 However,
there are restricted data about the role of LTB4 in
airway inflammation in asthma. Recently, Montuschi
and Barnes reported increased LTB4 levels in the
exhaled breath condensate of mild asthmatics com-
pared with normal healthy controls.
22 In our study,
we found increased LTB4 levels in all of the study
population when compared with controls and the
higher levels in NE asthma. Previous studies have
demonstrated that the LTB4 levels and neutrophil
counts were associated in patients with COPD.
16,23
Future studies are needed to determine the effects of
LTB4 in the pathogenesis of asthma.
Our results supported the previous data that
reported heterogeneity in airway inflammation in
asthma. Since we did not include the severe and mild
persistent asthmatics, it is difficult to clarify the
association between disease severity and neutrophilic
inflammation. However, based on previous data it is
possible to suggest that non-eosinophilic inflamma-
tion is more common than thought and it is even
observed in mild asthmatics. The inflammatory mar-
kers discussed previously might be the source of
neutrophil recruitment in the airways. However, it is
still unclear why these markers are involved in airway
inflammation in some asthmatics while others have
characteristic features of eosinophilic inflammation.
Possible explanations for neutrophilic inflamma-
tion in asthma include the effects of corticosteroids,
smoking, respiratory tract infection and atopy. Since
the prevalence of ex-smokers was similar between the
Table 3. Comparison of before and after treatment-induced sputum cells and inﬂammatory marker levels in eosinophilic and
non-eosinophilic subjects
Eosinophilic Non-eosinophilic
Before treatment After treatment p Before treatment After treatment p
Total cell count (  /10
6/g) 1.129 /0.5 0.59 /0.3 0.03* 1.759 /0.7 0.89 /0.4 0.01*
Eosinophil (%) 27.59 /14.2 16.49 /7 0.01* 49 /2.3 3.69 /2.5 0.70
Neutrophil (%) 209 /10.3 18.69 /11.2 0.06 509 /15 509 /13.5 0.20
Induced sputum
IL-8 5739 /173 4669 /118 0.01* 8629 /289 6459 /174 0.01*
TNF-a 4409 /120 3579 /105 0.01* 6249 /128 4739 /117 0.02*
LTB4 139 /9.3 4.59 /3.2 0.00* 189 /96 9 /4 0.00*
Serum
IL-8 2929 /133 2419 /141 0.05* 3289 /129 2379 /84 0.00*
TNF-a 2949 /102 2429 /89 0.00* 3919 /110 2719 /97 0.00*
LTB4 1.39 /0.5 0.69 /0.4 0.00* 1.39 /0.6 0.99 /0.5 0.00*
*pB /0.05, statistically significant.
*
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FIG. 2. Induced sputum eosinophil and neutrophil percen-
tages, comparison of before treatment (BT) and after treat-
ment (AT) levels in eosinophilic (E) and non-eosinophilic
(NE) subjects. *pB /0.05 before versus after treatment, **pB /
0.05 eosinophilic versus non-eosinophilic.
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important explanation for our study population.
Similarly, all inhaled corticosteroids withheld during
the run-in period, we also thought that the neutrophil-
predominated inflammation in our study is not due to
corticosteroid treatment. Although we excluded the
patients who had clinical evidence of a respiratory
tract infection, we could not exclude the possibility of
subclinical or viral infection of the lower respiratory
tract; infection is less likely to be a possible explana-
tion in this study. Similar with the previous reports, we
found that neutrophilic inflammation was higher in
non-atopic asthmatics than in the atopic subjects. Also
the duration of the disease was different between the
groups. Finally, we thought that non-atopic patients
with chronic asthma were more likely to have non-
eosinophilic inflammation.
Since corticosteroids are the main agents in asthma
treatment and there is some evidence that neutrophi-
lic inflammation is associated with a poor response to
steroids, we also investigated the effects of inhaled
steroids on non-eosinophilic airway inflammation.
Pavord et al. investigated the effects of inhaled
steroids on spirometric measurements, symptom
scores and induced sputum eosinophil counts in
eosinophilic and non-eosinophilic asthma.
15 They
found that NE asthma is associated with a poor
response to inhaled steroid and suggested that
sputum eosinophil count is an important factor in
determining the response to inhaled steroids in
asthma. Green et al. have reported similar findings;
they observed a significantly less improvement in VAS
(visual analogue symptom) scores and FEV1 levels in
the neutrophilic subgroup compared with the eosi-
nophilic subjects after 2 months treatment with
inhaled budesonide.
24 On the other hand. in a
recently published article Godon and coworkers
suggested that sputum eosinophilia is not always a
good indicator of a poor response to inhaled
steroids.
25 They investigated the effects of fluticasone
propionate on 51 mild uncontrolled, steroid-naı ¨ve
asthmatics and found that symptoms, quality of life,
FEV1 and PC20 (provocative concentration 20) were
improved both in eosinophilic and non-eosinophilic
asthmatics.
In our study, eosinophilic and non-eosinophilic
subjects were balanced with respect to improvement
in symptom scores and FEV1 levels. Induced sputum
total cell counts, IL-8, TNF-a and LTB4 levels
decreased significantly with the treatment and there
was no significant difference between the groups.
Previous studies have reported a decrease in IL-8
levels after corticosteroid treatment. This finding is
known to be associated with the suppression of IL-8
secretion from airway epithelial cells.
26 It was de-
monstrated that TNF-a plays an important role in
determining the severity of airway hyperreactivity in
asthma and it was also shown to decrease with the
treatment of inhaled steroids.
27,28
According to our knowledge this is the first study
that demonstrates a significant decrease in sputum
LTB4 levels with steroid treatment. It is thought that
steroid cannot inhibit the synthesis of lipid media-
tors.
23 However, we cannot identify the mechanism
of the decrease in LTB4 levels. It might be due to the
inhibition of phospholipase enzyme activation by
steroids.
In our study, we have found that response to
inhaled steroids is similar both in non-eosinophilic
and eosinophilic asthma. The most important insuffi-
ciency in our study is the lack of the parameters of
eosinophil activity. Although we have shown that the
sputum eosinophil count decreased significantly in
the eosinophilic group, we could not determine
whether eosinophilic inflammation parameters were
similar between the groups. On the other hand, we
have determined that IL-8, TNF-a and LTB4 levels
were associated with neutrophil recruitment in the
asthmatic airways and it is possible to suppress their
levels with steroid treatment.
In conclusion, we have suggested that there is a
non-eosinophilic subgroup in moderate asthma, but
their response to inhaled steroids is not significantly
different from those who have eosinophilic inflam-
mation.
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